Seattle genetics and beigene announce global license agreement for advanced preclinical product candidate

Seattle genetics and beigene announce global license agreement for advanced preclinical product candidate.seattle genetics - co, beigene entered agreement for an advanced preclinical product candidate for treating cancer.seattle genetics - co has retained rights to product candidate in americas, europe and japan.seattle genetics - beigene has been granted exclusive rights to develop and commercialize product candidate in asia and rest of world.seattle genetics - co will lead global development, beigene will fund, operationalize portion of clinical trials attributable to its territories.seattle genetics - co will receive upfront payment milestones, for a total deal value of up to $160 million and tiered royalties on any product sales.
SGEN Ratings Summary
SGEN Quant Ranking